Bayer AG has sold a minority stake in its contraceptives business to Apollo Global Management for €3 billion, a move aimed at strengthening its financial position amid ongoing litigation costs.

Context

The sale is part of Bayer's strategy to bolster its balance sheet after facing significant legal challenges related to its Roundup weedkiller product.S1S2

Key points

• Bayer sold a minority stake in its contraceptives business to Apollo Global Management.S1S2

• The transaction is valued at €3 billion, equivalent to $3.4 billion.S2

• Funds from the sale will be used to address litigation costs associated with Roundup.S1S2

• This sale is part of Bayer's broader financial strategy to improve its balance sheet.S1

• The deal highlights the ongoing financial pressures faced by Bayer due to legal issues.S2

• Apollo Global Management is a prominent investment firm involved in the transaction.S2

• Bayer's contraceptives business is a significant part of its overall portfolio.S1

• The sale reflects Bayer's efforts to navigate its financial challenges effectively.S1S2

Why it matters

• The sale helps Bayer manage its financial obligations amid costly litigation.S1S2

• Strengthening the balance sheet may improve Bayer's market position and investor confidence.S1

What to watch

• Monitor Bayer's financial performance post-sale and its impact on litigation costs.S1S2

• Watch for any further strategic moves by Bayer in response to ongoing legal challenges.S1